High sporulation and overexpression of virulence factors in biofilms and reduced susceptibility to vancomycin and linezolid in recurrent Clostridium [Clostridioides] difficile infection isolates [PDF]
, 2019 Clostridium [Clostridioides] difficile infection (CDI) is one of the leading causes of diarrhea associated with medical care worldwide, and up to 60% of patients with CDI can develop a recurrent infection (R-CDI). A multi-species microbiota biofilm model
Baines, Simon +9 more
core +1 more source
Trends in U.S. Burden of Clostridioides difficile Infection and Outcomes.
New England Journal of Medicine, 2020 BACKGROUND Efforts to prevent Clostridioides difficile infection continue to expand across the health care spectrum in the United States. Whether these efforts are reducing the national burden of C. difficile infection is unclear.
A. Guh +14 more
semanticscholar +1 more source
Gut microbes, 2023 Clostridioides difficile is a pathogen contributing to increased morbidity and mortality of patients with inflammatory bowel disease (IBD). To determine how C.
Danfeng Dong +9 more
semanticscholar +1 more source
Uncovering the Harms of Treating Clostridioides difficile Colonization
mSphere, 2021 Patients with toxin-negative Clostridioides ...
Christopher R. Polage +1 more
doaj +1 more source
Anaerobic 4-hydroxyproline utilization: Discovery of a new glycyl radical enzyme in the human gut microbiome uncovers a widespread microbial metabolic activity. [PDF]
, 2018 The discovery of enzymes responsible for previously unappreciated microbial metabolic pathways furthers our understanding of host-microbe and microbe-microbe interactions. We recently identified and characterized a new gut microbial glycyl radical enzyme
Balskus, Emily P +2 more
core +1 more source
Food for thought—The link between Clostridioides difficile metabolism and pathogenesis
PLoS Pathogens, 2023 Clostridioides difficile (C. difficile) is an opportunistic pathogen that leads to antibiotic-associated diarrhoea and is a leading cause of morbidity and mortality worldwide. Antibiotic usage is the main risk factor leading to C.
A. Marshall +3 more
semanticscholar +1 more source
Efficacy of bezlotoxumab in preventing the recurrence of Clostridioides difficile infection: an Italian multicenter cohort study [PDF]
, 2023 Objectives: Bezlotoxumab (BEZ) is a promising tool for preventing the recurrence of Clostridioides difficile infection (rCDI). The aim of the study was to emulate, in a real-world setting, the MODIFY trials in a cohort of participants with multiple risk ...
Barchiesi, F +19 more
core +4 more sources
Developing Gut Microbiota Exerts Colonisation Resistance to Clostridium (syn. Clostridioides) difficile in Piglets [PDF]
, 2019 Clostridium (syn. Clostridioides) difficile is considered a pioneer colonizer and may cause gut infection in neonatal piglets. The aim of this study was to explore the microbiota-C. difficile associations in pigs.
Dadi, Temesgen Hailemariam +3 more
core +1 more source
Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice [PDF]
, 2023 INTRODUCTION Faecal microbiota transplantation (FMT) is an established therapy for recurrent C. difficile infection, and recent studies have reported encouraging results of FMT in patients with ulcerative colitis.
Burri, Emanuel +10 more
core +1 more source
Clostridioides difficile Infection in Children: Recent Updates on Epidemiology, Diagnosis, Therapy
Pediatrics, 2023 Clostridioides (formerly Clostridium) difficile is the most important infectious cause of antibiotic-associated diarrhea worldwide and a leading cause of healthcare-associated infection in the United States. The incidence of C.
D. Shirley +3 more
semanticscholar +1 more source